HC Wainwright Has Bearish Forecast for CNTX FY2024 Earnings

Context Therapeutics Inc. (NASDAQ:CNTX) – Stock analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for Context Therapeutics in a research report issued on Thursday, November 7th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.53) for the year, down from their prior estimate of ($0.52). HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q4 2024 earnings at ($0.04) EPS, FY2025 earnings at ($0.37) EPS, FY2026 earnings at ($0.52) EPS and FY2027 earnings at ($0.64) EPS.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.11).

Context Therapeutics Stock Performance

Shares of CNTX stock opened at $1.95 on Monday. The stock has a market cap of $146.25 million, a PE ratio of -2.14 and a beta of 2.25. Context Therapeutics has a 1 year low of $0.77 and a 1 year high of $2.75. The stock has a fifty day moving average price of $2.09 and a 200 day moving average price of $2.07.

Institutional Trading of Context Therapeutics

Several large investors have recently modified their holdings of the business. Renaissance Technologies LLC lifted its stake in Context Therapeutics by 63.4% in the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after buying an additional 25,300 shares in the last quarter. Opaleye Management Inc. raised its holdings in shares of Context Therapeutics by 13.7% in the first quarter. Opaleye Management Inc. now owns 1,108,357 shares of the company’s stock worth $1,530,000 after acquiring an additional 133,357 shares during the last quarter. Affinity Asset Advisors LLC lifted its position in shares of Context Therapeutics by 392.4% in the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock valued at $3,246,000 after acquiring an additional 1,290,323 shares in the last quarter. Ally Bridge Group NY LLC boosted its stake in shares of Context Therapeutics by 159.8% during the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock valued at $3,782,000 after acquiring an additional 1,160,281 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in Context Therapeutics during the 2nd quarter worth about $3,881,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.